Policy & Regulation
MilliporeSigma partners with Baylor College of Medicine to advance vaccine manufacturing platform to fight COVID-19
28 May 2020 -

Life science company MilliporeSigma said on Wednesday that it has extended its ongoing collaboration with Baylor College of Medicine to advance a manufacturing platform to develop a safe and effective COVID-19 vaccine and transition to Phase 1 clinical trials.

Using key learnings from their ongoing collaboration on a schistosomiasis vaccine, MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two COVID-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate expected to enter clinical trials later this year.

As part of the agreement, MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. The collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs. The goal for the partnership is to develop a suitable manufacturing process and steps that would lead to a scale-up approach suitable for pilot and later industrial production.

Additionally, the partners will develop a new manufacturing platform for a second COVID-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.

MilliporeSigma is the life science business of Merck KGaA (ETR:MRK).